

## **Inhibition of Anthracycline Alcohol Metabolites Formation in Human Heart Cytosol: a Potential Role for Several Promising Drugs**

Alvaro Mordente, Andrea Silvestrini, Giuseppe Ettore Martorana, Daniela Tavian, and Elisabetta Meucci

Institute of Biochemistry and Clinical Biochemistry, School of Medicine, Catholic University, Largo F. Vito 1, 00168, Roma, Italy (A.M., A.S., G.E.M., E.M.); Laboratory of Cellular Biochemistry and Molecular Biology, CriBeNS, Catholic University, Largo A. Gemelli, 1, 20123, Milan, Italy (D.T.).

Running title: ANTHRACYCLINE REDUCTIVE METABOLISM IN HUMAN HEART

**Address correspondence to:**

Prof. Alvaro Mordente, Institute of Biochemistry and Clinical Biochemistry, School of  
Medicine, Catholic University, Largo F. Vito 1, 00168, Rome, Italy.

E-mail: [alvaro.mordente@rm.unicatt.it](mailto:alvaro.mordente@rm.unicatt.it)

Andrea Silvestrini, Institute of Biochemistry and Clinical Biochemistry, School of  
Medicine, Catholic University, Largo F. Vito 1, 00168, Rome, Italy.

E-mail: [asilvestrini@rm.unicatt.it](mailto:asilvestrini@rm.unicatt.it)

Text pages = 23

Tables = 2

Figures = 10

References = 74

Abstract = 200 words

Introduction = 742 words

Discussion = 1568 words

**ABBREVIATIONS:** AKR, aldo-keto reductase; CBR, carbonyl reductase; CoQ, coenzyme Q; cyPG, cyclopentenone prostaglandin; DB, decylubiquinone; DEANO, diethylamine NONOate; DNR, daunorubicin; DNRol, daunorubicinol; DOX, doxorubicin; DOXol, doxorubicinol; DTT, dithiothreitol; GSNO, S-nitrosoglutathione; HNE, 4-hydroxy-2-nonenal; IDB, idebenone; NEM, N-ethylmaleimide; NO, nitric oxide; PBN, N-t-butyl- $\alpha$ -phenyl-nitron; PG, prostaglandin; p-HMB para-hydroxymercuric benzoic acid; POBN,  $\alpha$ -(4-pyridyl, 1-oxide)-N-tert-butyl nitron; ROS, reactive oxygen species; SDR, short-chain reductase\dehydrogenase; SNAP, ( $\pm$ )-S-nitroso-N-acetylpenicillamine.

## **ABSTRACT**

The clinical efficacy of anthracyclines (e.g. doxorubicin and daunorubicin) in cancer therapy is limited by their severe cardiotoxicity, the aetiology of which is still not fully understood. The development of anthracycline-induced cardiomyopathy has been found to correlate with myocardial formation and accumulation of anthracycline secondary alcohol metabolites (e.g. doxorubicinol and daunorubicinol) that are produced by distinct cytosolic NADPH-dependent reductases. The aim of the current study is to identify chemical compounds capable of inhibiting myocardial reductases implied in anthracycline reductive metabolism in the attempt to decrease the production of cardiotoxic C-13 alcohol metabolites. Among the variety of tested compounds (metal chelators, radical scavengers, antioxidants,  $\beta$ -blockers, nitron spin traps and lipid-lowering drugs), ebselen, cyclopentenone prostaglandins, nitric oxide donors and short-chain coenzyme Q analogs resulted effective inhibitors of both doxorubicinol and daunorubicinol formation. In particular, ebselen (as well as ebselen diselenide, its storage form in the cells) was the most potent inhibitor of cardiotoxic anthracycline alcohol metabolites with a 50 % inhibition of doxorubicinol formation at 0.2 molar equivalents of ebselen in respect to doxorubicin concentration. The high efficacy, together with its favorable pharmacological profile (low toxicity, lack of adverse effects, metabolic stability) portends ebselen as a promising cardioprotective agent against anthracycline-induced cardiotoxicity.

## Introduction

The anthracycline antibiotics doxorubicin (DOX) and daunorubicin (DNR) are among the most potent anticancer drugs ever developed and, in spite of half a century of clinical use, they continue to play, either individually or in combination with other chemotherapeutics, an undisputed role in the treatment of a variety of haematological neoplasms and solid tumors (Minotti et al., 2004; Gianni et al., 2008; Blanco et al., 2012). Anthracyclines, moreover, are an essential component of childhood cancer therapy, as evidenced by their incorporation into more than 50% of front-line therapeutic regimens (Blanco et al., 2012). Unfortunately, the clinical utility of anthracyclines is severely limited by their selective toxicity for myocardial tissue, leading to a progressive cardiomyopathy that irreversibly evolves to congestive heart failure (Minotti et al., 2004; Gianni et al., 2008; Menna et al., 2011; Blanco et al., 2012).

Although the aetiopathogenesis of anthracycline-related cardiomyopathy has been not yet completely elucidated (Minotti et al., 2004; Gianni et al., 2008; Mordente et al., 2009; Menna et al., 2011), the cardiotoxicity is thought to be due to a multifactorial process that correlates with myocardial accumulation of anthracyclines, their by-products and/or their metabolites (Minotti et al., 2004; Salvatorelli et al., 2006; Gianni et al., 2008; Menna et al., 2008; Mordente et al., 2009; Menna et al., 2011; Octavia et al., 2012). Current thinking is that anthracyclines are cardiotoxic *per se*, but develop further toxicity after intracellular activation by reductive metabolism (Salvatorelli et al., 2006; Menna et al., 2008; Mordente et al., 2009; Menna et al., 2011). One-electron reduction of the quinone moiety of anthracyclines and the subsequent semiquinone redox-cycling result in reactive oxygen species (ROS) overproduction that causes oxidative stress and energy depletion in cardiomyocytes (Minotti et al., 2004; Tokarska-Schlattner et al., 2006; Gianni et al., 2008; Mordente et al., 2009; Octavia et al., 2012). Alternatively, two-electron reduction

of the side-chain C-13 carbonyl group converts anthracyclines to their secondary alcohol metabolites, doxorubicinol (DOXol) or daunorubicinol (DNRol), that are much less effective in killing cancer cells (Heibein et al., 2012) but remarkably more potent than their parent compounds at impairing myocardial cells calcium (Menna et al., 2011; Octavia et al., 2012) and iron homeostasis (Minotti et al., 1998; Minotti et al., 2004). Oxidative stress (Minotti et al., 2004; Salvatorelli et al., 2006; Gianni et al., 2008; Menna et al., 2011; Octavia et al., 2012), mitochondrial dysfunction (Tokarska-Schlattner et al., 2006; Mordente et al., 2012), energy depletion (Minotti et al., 2004; Tokarska-Schlattner et al., 2006), ions dysregulation (Minotti et al., 2004; Menna et al., 2011) and concomitant alterations of the cardiospecific signalling pathways (Mordente et al., 2012) can be also assumed to be part of the multifactorial process that eventually leads to cardiomyopathy.

The involvement of secondary alcohol metabolites in anthracycline-induced cardiomyopathy is indicated by several biochemical, pharmacokinetic, and genetic evidence (Minotti et al., 2004; Salvatorelli et al., 2006; Gianni et al., 2008; Mordente et al., 2009; Ferguson et al., 2015). Anthracycline alcohol metabolites formation is catalyzed mainly by distinct cytosolic NADPH-dependent oxidoreductases (Mordente et al., 2003; Jin and Penning, 2007; Oppermann, 2007; Bains et al., 2010; Malatkova et al., 2010; Blanco et al., 2012) that metabolize a broad range of endogenous and exogenous carbonyl-containing compounds, including steroids, eicosanoids, cofactors, neurotransmitters and polyols (Jin and Penning, 2007; Oppermann, 2007; Bains et al., 2010; Malatkova et al., 2010). Moreover, the conversion of C-13 carbonyl moiety into an alcohol group renders anthracycline secondary alcohol metabolites appreciably more polar than the parent drugs (Salvatorelli et al., 2007; Gianni et al., 2008; Menna et al., 2008). Accordingly, anthracycline alcohol metabolites, due to their lowered clearances,

tend to accumulate in cardiomyocytes forming a long-lived drug reservoir that eventually represents the only or prevailing remnant of an anthracycline treatment (Gianni et al., 2008; Menna et al., 2008). Therefore, the unique pharmacokinetic characteristics of secondary alcohol metabolites might explain how anthracycline regimens foreshadow a lifelong risk of cardiotoxicity (Gianni et al., 2008; Menna et al., 2008).

The aforesaid reasoning indicates that inhibitors of myocardial reductases might be useful in mitigating cardiotoxicity and improving the therapeutic index of these anticancer drugs. Although this attractive strategy has been repeatedly prompted, the data are still scarce and often disappointing (Tanaka et al., 2005; Silvestrini et al., 2006).

In the present study we have, therefore, characterized several compounds capable of inhibiting human heart cytosolic reductases involved in anthracycline carbonyl reduction in order to decrease the production of toxic C-13 alcohol metabolites responsible for anthracycline-induced cardiomyopathy.

## Materials and Methods

**Chemicals.** Doxorubicin, doxorubicinol, daunorubicin and daunorubicinol were kindly provided by Nerviano Medical Sciences (Milan, Italy). Anthracycline stock solutions were prepared in 18.2 MΩ·cm double-distilled deionized water (Milli-Q, Millipore, Bedford, MA) and shown to be stable for at least 1 month if stored at + 4 °C in the dark. Melatonin, 2-cyclopenten-1-one, cyclopentene, cyclopentanone, 1-octenen-3-ol, oenanthic acid, sodium dihydrogen phosphate monohydrate (NaH<sub>2</sub>PO<sub>4</sub>·H<sub>2</sub>O), 85% orthophosphoric acid, NADPH (tetrasodium salt), HEPES, ammonium sulfate, 2-phenyl-1,2-benzisoxselenazol-3[2H]-one (Ebselen), sodium chloride, bovine serum albumin, EDTA (disodium salt), dicumarol, para-hydroxymercuric benzoic acid (p-HMB), N-ethylmaleimide (NEM), dimethyl sulfoxide, all *trans*-Retinal (Vitamin A aldehyde), N-*t*-butyl- $\alpha$ -phenyl-nitron (PBN), dithiothreitol (DTT), 2-(3-Aminopropyl) aminoethylphosphorothioate (amifostine), DL- $\alpha$ -Tocopherol, ( $\pm$ )-6-Hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid (Trolox), mevinolin (Lovastatin), mevastatin;  $\alpha$ -(4-pyridyl, 1-oxide)-N-*t*-butylnitron (POBN), adenosine, 4-hydroxy-2-nonenal, ethacrynic acid, acrolein, decylubiquinone (DB) and GSH were purchased from Sigma-Aldrich Co. (St. Louis, MO); L-sepiapterin, diethylamine NONOate (DEANO), prostaglandin A<sub>1</sub> (PGA<sub>1</sub>), A<sub>2</sub> (PGA<sub>2</sub>), B<sub>1</sub> (PGB<sub>1</sub>), B<sub>2</sub> (PGB<sub>2</sub>), D<sub>1</sub> (PGD<sub>1</sub>), D<sub>2</sub> (PGD<sub>2</sub>), E<sub>1</sub> (PGE<sub>1</sub>), E<sub>2</sub> (PGE<sub>2</sub>), J<sub>2</sub> (PGJ<sub>2</sub>), 15-deoxy- $\Delta^{12,14}$ -PGJ<sub>2</sub> (15d-PGJ<sub>2</sub>) and 9,10-dihydro-15-deoxy- $\Delta^{12,14}$ -PGJ<sub>2</sub> and  $\Delta^{12}$ -PGJ<sub>2</sub> were from Cayman Chemicals (Ann Arbor, MI); S-nitrosoglutathione (GSNO) and ( $\pm$ )-S-nitroso-N-acetylpenicillamine (SNAP) were from Calbiochem (Darmstadt, Germany); HPLC-grade acetonitrile and chloroform and disodium hydrogen phosphate 12-hydrate (Na<sub>2</sub>HPO<sub>4</sub> · 12 H<sub>2</sub>O) were from Merck; ethyl alcohol absolute for spectrophotometry was from Carlo Erba (Milan, Italy); 1-heptanol was from BDH (Poole, UK); Bicinchoninic acid protein assay reagent kit was purchased

from Pierce (Rockford, IL). 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone, Idebenone (IDB) was kindly provided by Takeda Pharmaceutical Co. (Tokyo, Japan). Coenzyme Q<sub>10</sub> (CoQ<sub>10</sub>), Q<sub>0</sub>, Q<sub>1</sub>, Q<sub>2</sub>, Q<sub>4</sub>, Q<sub>6</sub> (short chain coenzyme Q analogs) and Carvedilol were a generous gift from Hoffmann-La Roche (Basel, Switzerland), and Dexrazoxane (Cardioxane) from Chiron (Milan, Italy). Ebselen diselenide was a kind gift from Arne Holmgren, (Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden).

Reduced form of coenzyme Q was prepared as described by Mordente et al (Mordente et al., 1994).

**Preparation of cytosolic fractions.** Human heart ventricular samples (10-20 g) were obtained during authorized autopsies at the Department of Forensic Medicine of the Catholic University School of Medicine. Tissue removal and examination were in accordance to the Institutional Ethical Guidelines for the use of human tissues for teaching and research purposes. The study has been carried out in accordance with The Declaration of Helsinki. Samples derived from 20-40 yr male ( $n = 3$ ) or female ( $n = 2$ ) individuals with morphologically normal myocardium and no clinical history of acute myocardial infarction, severe atherosclerosis or other cardiomyopathies. All samples were collected 24 h after death and stored at -80°C until use. Heart samples were carefully rinsed in ice-cold saline and homogenized in 4 volumes of ice-cold 10 mM HEPES buffer (pH 7.4), containing 0.3 M NaCl and 0.5 mM EDTA, using an Ultra Turrax and a glass-teflon Potter-Elvehjem homogenizer. Cytosolic fractions were prepared by sequential centrifugation, 20 min at 8,500 g and 23,000 g, and 90 min ultracentrifugation at 140,000 g, all in 0.3 M NaCl-10 mM HEPES, pH 7.4 (standard buffer). Next, 140,000 g supernatants were stirred overnight with 65% ammonium sulfate and centrifuged at 10,000 g for 20 min. Protein precipitates were suspended in 5-6 ml of homogenization buffer,



dialyzed against three one-liter changes of the same buffer added with 1 mM EDTA (to remove adventitious iron) and then against three one-liter changes of EDTA-free buffer (to remove EDTA and EDTA-iron complexes) (Mordente et al., 2003). After low speed centrifugation to remove any insoluble material, cytosolic proteins were assayed by the bicinchoninic acid method against bovin serum albumin standard curves and stored in aliquots at -80 °C until use.

**Effect of tested compounds on anthracycline secondary alcohol metabolites formation.** The effect of xenobiotics on anthracycline metabolism was characterized in incubation mixtures that contained human heart cytosol (1.0 mg protein/ml) and xenobiotic (or vehicle) in standard buffer, at 37°C. The incubation time and the concentration of each tested compound are specified in the legends of Figures or Tables.

At the indicated time intervals, 50 µM (final concentration) DOX or DNR was added into the incubation mixture and the reaction was started by adding 250 µM (final concentration) NADPH.

After 240 min at 37°C, aliquots (500 µl) were withdrawn from the incubation mixture and assayed for anthracycline secondary alcohol metabolites as described below.

Where indicated, the IC<sub>50</sub> values (the concentration of the inhibitor required to produce 50% inhibition of anthracycline alcohol metabolite formation) were determined by nonlinear regression analysis of the dose-inhibition curves. Each curve was obtained using at least eight concentrations of xenobiotic. All values were the means ± S.E. of three separate experiments performed in triplicate.

To identify the inhibition mechanism of ebselen and ebselen diselenide and to calculate the inhibition constants, the formation of anthracycline alcohol metabolites was measured in the absence or in the presence of different concentrations of drug by varying DOX concentration (25-500 µM) at a fixed concentration of NADPH (250 µM). Results were

presented as double-reciprocal Lineweaver-Burk plots. Inhibition constants ( $K_i$ ) were determined by simultaneously fitting the untransformed data (i.e., control and inhibition data set) to competitive, uncompetitive, noncompetitive, and mixed enzyme inhibition equations using a nonlinear regression program (GraphPad Prism 4.0, Graphpad Software, San Diego, CA).

Other experimental conditions are given in the legends of the Figures or Tables.

**Effect of nitric oxide donors on anthracycline secondary alcohol metabolites formation.** Human heart cytosolic fractions (1.0 mg protein/ml) were incubated at 37°C in the absence (vehicle) or in the presence of varying concentrations of nitric oxide donors. Aliquots were withdrawn from the incubation mixture and nitric oxide donor was removed by 3 cycles of concentration-dilution into standard buffer using a microcentrifugal concentration device with a 10 kDa cutoff membrane (Centricon, Millipore, Bedford, MA). After re-adjusting protein concentration (1 mg/ml, final concentration), 50  $\mu$ M (final concentration) either DOX or DNR was added into the mixture and the reaction was started by adding 250  $\mu$ M (final concentration) NADPH. Incubation conditions and metabolite extraction were the same as described under assay for anthracycline secondary alcohol metabolites.

The concentrations of GSNO and SNAP were determined by absorption using  $\epsilon_{330\text{nm}} = 767$  and  $717 \text{ M}^{-1} \text{ cm}^{-1}$ , respectively (Tao and English, 2004).

Fresh GSNO solutions were prepared in MilliQ water just before being used and kept on ice and always protected from light. Decomposed GSNO was prepared by storing aqueous solutions at room temperature in the dark for 72h (72h-decomposed GSNO) (Tao and English, 2004).

**HPLC assay for anthracycline secondary alcohol metabolites.** Unless otherwise indicated, the reaction mixture (500  $\mu$ l) was stopped by adding an equal volume of 0.2 M

Na<sub>2</sub>HPO<sub>4</sub>, pH 8.4, and samples were extracted with 4 ml of a 9:1 (v/v) chloroform/1-heptanol mixture. After vigorous shaking (15 min), samples were centrifuged at 4000 rpm for 10 minutes at 20 °C to separate an upper aqueous phase and a lower organic phase. The aqueous phase was recovered and assayed spectrophotometrically for the determination of NADPH content. The organic phase was re-extracted with 250 µl of 0.1 M orthophosphoric acid and vortexed vigorously for 1 min at room temperature to obtain an upper aqueous layer from which 50 µl were eventually removed and used for HPLC analysis as previously described (Mordente et al., 2003; Silvestrini et al., 2006). The chromatographic apparatus consisted of an Agilent 1200 system (Agilent Technologies, Santa Clara, CA) equipped with diode array and fluorescence detectors. Reverse-phase chromatography was performed with an Agilent ZORBAX CN column (250 x 4.6 mm, 5 µm) protected by a ZORBAX CN analytical guard column (12.5 x 4.6 mm, 5 µm). Isocratic elution was performed at 1 ml/min with a daily prepared mobile phase consisting of a 75:25 (v:v) mixture of 50 mM sodium dihydrogen phosphate:acetonitrile, adjusted to pH 4.0 with orthophosphoric acid and filtered through a 0.22 µm membrane (Millipore, Bedford, MA). C-13 alcohol metabolites were detected fluorimetrically with excitation at 480 nm and emission at 560 nm and quantified against appropriate standard curves. Retention times were as follow: DOX 10 min, DOXol 6 min, DNR 18 min, DNRol 9 min. Incubation mixtures lacking cytosol or NADPH were also included as blanks. Whatever the experimental conditions employed, the formation of anthracycline alcohol metabolites linearly increased during the incubation period (240 min).

**Statistical Analysis.** All values were the means ± S.E. of three separate experiments performed in triplicate. Data were analyzed by unpaired Student's t test, and statistical probability (*P*) was expressed as follows: \* *P* < 0.05, \*\* *P* < 0.01, and \*\*\**P* < 0.001.

## Results

**Effect of various drugs on the formation of anthracycline secondary alcohol metabolites.** We have initially screened a variety of drugs (metal chelators, radical scavengers, antioxidants,  $\beta$ -blockers, nitron spin traps and lipid-lowering drugs), known to mitigate anthracycline-induced cardiotoxicity in animal models and/or in humans (Minotti et al., 2004; van Dalen et al., 2011; Cardinale et al., 2013). These studies, however, are still few and are often reporting conflicting results between preclinical models and clinical settings (Minotti et al., 2004; Menna et al., 2011; van Dalen et al., 2011; Cardinale et al., 2013).

With the only exception of all-trans retinal, which slightly inhibited DNRol but not DOXol formation, none of the compounds reported in Table 1 significantly affected anthracycline secondary alcohol metabolites formation in our experimental model.

Conversely, ebselen, cyclopentenone prostaglandins, nitric oxide donors, and short-chain coenzyme Q analogs resulted efficient inhibitors of both DOXol and DNRol formation (see below).

**Effect of ebselen.** Ebselen is a synthetic organo-selenium compound (see structure in Figure 1) that exhibits antioxidant, anti-inflammatory and cytoprotective properties in a variety of animal models (Sakurai et al., 2006; Sarma and Mugesh, 2008). Moreover, unlike other selenium compounds, ebselen displays a very low toxicity due to its great structural stability that does not allow the selenium moiety to be released during drug transformation and does not impair selenium metabolism (Sies and Masumoto, 1997; Zhao and Holmgren, 2002). Accordingly, ebselen is well tolerated in humans and has been successfully used in phase III clinical trials for the treatment of patients with acute ischemic stroke (Yamaguchi et al., 1998) or delayed neurological deficits after aneurismal subarachnoid hemorrhage (Saito et al., 1998).

Interestingly, ebselen significantly ameliorated anthracycline-induced cardiomyopathy in animal models, but the molecular mechanism of this cardioprotective effect is still unclear (Pritsos et al., 1992; Saad et al., 2006).

As shown in Figure 2A, ebselen inhibited anthracycline alcohol metabolites formation in a dose-dependent manner, displaying a higher efficacy on DOXol ( $IC_{50} = 9.8 \pm 0.7 \mu M$ ) than on DNRol ( $IC_{50} = 32.7 \pm 5.6 \mu M$ ) production.

In our experimental conditions (i.e.  $50 \mu M$  anthracycline), about 50% inhibition of DOXol formation was achieved with 0.2 molar equivalents of ebselen in respect to DOX concentration. Accordingly, since during chemotherapy DOX concentration reaches an intracellular level of approximately  $1 \mu M$ , speculatively  $0.2 \mu M$  ebselen might thus be enough to inhibit significantly DOXol formation *in vivo*.

The ebselen-induced inhibition occurred quickly and the extent of inhibition did not depend on the duration of the pre-incubation period (from 5 to 60 min) as well as on the presence of anthracycline (see just below and later on in the discussion section), NADPH or both in the reaction mixture (data not shown). Accordingly, a double-reciprocal Lineweaver-Burk plot (Figure 3A) showed that ebselen inhibited DOXol formation by a noncompetitive mechanism ( $K_i = 5.586 \pm 0.254 \mu M$ ). The same inhibition behavior has been already observed for other enzymes treated with ebselen (Schewe et al., 1994; Semianrio-Vidal et al., 2010). Moreover, the inhibition was irreversible because ultrafiltration or long-term dialysis of ebselen-treated heart cytosolic fractions failed to restore anthracycline reductase activity (activity recovery was less than 5 %).

In addition, when the ebselen-inactivated cytosolic fractions were treated with 5 mM DTT or 5 mM GSH for 4 h at  $37^\circ C$ , only a partial recovery of the original anthracycline reductase activity was observed ( $28 \pm 6 \%$  with DOX and  $23 \pm 5 \%$  with DNR after DTT treatment and  $25 \pm 3 \%$  with DOX and  $24 \pm 5 \%$  with DNR after GSH treatment).

The chemistry of ebselen is considered complex and still controversial under several viewpoints (Sakurai et al., 2006; Sarma and Mugesh, 2008). In fact, although, most of the biological activities of ebselen seem to be related to its ability to quickly react with protein and nonprotein thiol groups, GSH included (Sakurai et al., 2006; Sarma and Mugesh, 2008), the details of these reactions remain obscure, mainly for the lack of undoubted identification of the reaction intermediates. According to the revised catalytic mechanism, ebselen rapidly reacts with GSH to produce the corresponding selenenyl sulfide derivative that undergoes a disproportionation reaction to produce ebselen diselenide, which is now considered the storage form of ebselen in the cells (Sarma and Mugesh, 2008). We have therefore investigated the effect of ebselen diselenide on anthracycline alcohol metabolite formation by human heart cytosolic fractions. As shown in Figure 2B, ebselen diselenide (which, due to its low water solubility, cannot be used at concentrations higher than 10  $\mu\text{M}$ ) was a powerful inhibitor of both DOXol ( $\text{IC}_{50} = 5.3 \pm 1.1 \mu\text{M}$ ) and DNRol ( $\text{IC}_{50} = 11.6 \pm 4.1 \mu\text{M}$ ) formation with higher efficiency (about double) than that of ebselen. Similarly to ebselen, ebselen diselenide behaves as a noncompetitive inhibitor ( $\text{K}_i = 3.782 \pm 0.189 \mu\text{M}$ ) of doxorubicin reductase activity (Figure 3B).

To confirm the importance of cysteine residues for the catalytic activity of the reductases involved in anthracycline metabolism, human heart cytosolic fractions were treated with the thiol alkylating agent N-ethylmaleimide (NEM) and with the thiol-specific blocker para-hydroxymercuric benzoic acid (p-HMB). Both NEM (50  $\mu\text{M}$ ) and p-HMB (50  $\mu\text{M}$ ) strongly inhibited DOXol formation ( $90 \pm 6\%$  and  $88 \pm 5\%$ , respectively) and DNRol formation ( $91 \pm 5\%$  and  $87 \pm 6\%$ , respectively).

**Effect of cyclopentenone prostaglandins.** Prostaglandins are a family of biologically active eicosanoids that are involved in the regulation of numerous physiopathological

processes, including inflammation, cellular growth and differentiation (Sanchez-Gomez et al., 2010; Garzon et al., 2011; Diez-Dacal and Perez-Sala, 2012). Within PGs family, the A and J series, known as cyclopentenone prostaglandins (cyPGs), possess an  $\alpha,\beta$ -unsaturated carbonyl group in the cyclopentene ring which confers them a high reactivity toward nucleophiles, such as thiol groups, and can lead to the formation of covalent adducts by Michael addition reactions (Sanchez-Gomez et al., 2010; Garzon et al., 2011; Diez-Dacal and Perez-Sala, 2012).

Post-translational modification of proteins by cyPGs (referred as prostanylation or eicosanylation) affects the function of specific transcription factors, tumor suppressors and antioxidant enzymes and seems therefore responsible for several of the biological effects of cyPGs (Garzon et al., 2011; Diez-Dacal and Perez-Sala, 2012). These findings have led to the proposal of employing cyPGs as potential therapeutic agents in the treatment of pathological conditions with inflammatory or proliferative components like cancer (Diez-Dacal et al., 2011; Diez-Dacal and Perez-Sala, 2012).

In this work, we studied the effects of different classes of PGs on anthracycline alcohol metabolites formation in human heart cytosolic fractions, also in view of findings that raise the possibility of protecting the heart of patients undergoing DOX treatment by PGs co-administration (Dowd et al., 2001; Neilan et al., 2006).

As shown in Figure 4, PGs of the A and J series ( $\text{PGA}_1$ ,  $\text{PGA}_2$ ,  $\text{PGJ}_2$ ,  $15\text{d-PGJ}_2$  and  $\Delta^{12}\text{-PGJ}_2$ ) with the exception of 9,10-dihydro-15d-PGJ<sub>2</sub> (see below), strongly decreased DOXol formation (Fig. 4A), whereas a lower effect was observed on DNRol production for  $\text{PGA}_1$  and  $\text{PGA}_2$  (Fig. 4B). Conversely, PGs of the B, D and E series were completely ineffective on both DOXol (Fig. 4A) and DNRol (Fig. 4B) formation. For the sake of clarity, only  $\text{PGB}_1$ ,  $\text{PGD}_1$  and  $\text{PGE}_1$  are shown in Figure 4, whereas  $\text{PGB}_2$ ,  $\text{PGD}_2$ , and  $\text{PGE}_2$  are not shown.

The inhibitory effects of cyPGs on DOXol (Fig. 5A) and DNRol (Fig. 5B) formation were dose-dependent, showing saturation kinetics, except for  $\Delta^{12}$ -PGJ<sub>2</sub> (see again Fig. 5B). It is noteworthy, however, that cyPGs, even at the highest concentrations employed, did not completely inhibit DNRol formation (Fig. 5B).

As evidenced by IC<sub>50</sub> values (Fig. 6), the inhibitory potency of cyPGs on DOXol formation decreased in the following order: PGA<sub>1</sub> > PGA<sub>2</sub> > PGJ<sub>2</sub> > 15d-PGJ<sub>2</sub> >  $\Delta^{12}$ -PGJ<sub>2</sub>.

To further characterize the structural determinants responsible for cyPGs inhibitory activity, we treated heart cytosolic fractions with 2-cyclopenten-1-one, cyclopentanone and cyclopentene, three chemical compounds containing different five-member ring moieties, but all lacking aliphatic side chains typical of the eicosanoid structure. Again, cytosolic fractions were also treated with 1-octen-3-ol and oenanthalic acid, whose chemical structure resembles that of the two aliphatic side chains of PGA<sub>1</sub>.

2-cyclopenten-1-one actually inhibited both DOXol (IC<sub>50</sub> = 8.8 ± 0.45 mM) and DNRol (IC<sub>50</sub> = 9.1 ± 0.44 mM) formation but at much higher concentrations (about 150 fold) than PGA<sub>1</sub> or PGA<sub>2</sub>. Similar results were obtained by Strauss et al. (Strauss et al., 2000), who observed that 100-200 fold higher concentrations of 2-cyclopenten-1-one in comparison to 15d-PGJ<sub>2</sub> were needed to inhibit NF- $\kappa$ B activation. Conversely, neither cyclopentanone (a compound similar to 2-cyclopenten-1-one, but containing a saturated five member ring) nor cyclopentene (a five-member ring system containing a double bond, but not a carbonyl group) affected anthracycline alcohol metabolites formation. Similarly, neither 1-octen-3-ol nor oenanthalic acid were able to decrease DOXol or DNRol production (less than 3 % inhibition at 250  $\mu$ M, final concentration).

**Effect of nitric oxide donors.** Nitric oxide (NO) is an endogenous cell-signaling molecule essential for the integrity of the cardiovascular system, and decreased production and/or bioavailability of NO lead to the development of cardiovascular



diseases and heart failure (Zhu et al., 2011). Moreover, NO sensitizes tumor cells to ionizing radiation and photodynamic therapy and increases anticancer activity of several chemotherapeutic agents, anthracyclines included (Matthews et al., 2001; Frederiksen et al., 2003). Accordingly, NO donors could be promising therapeutic agents against anthracycline-induced cardiotoxicity (Zhu et al., 2011) and multidrug resistance in tumor cells (de Luca et al., 2011).

In addition to the classic cGMP-dependent pathway, NO also regulates cell function through protein S-nitrosylation (also referred to as S-nitrosation), a reversible, redox-dependent, posttranslational protein modification that involves attachment of an NO group to a nucleophilic protein sulfhydryl group (Tao and English, 2004; Hartmanova et al., 2013).

In particular, NO donors modulate AKR activity leading to either activation or inhibition, depending on the chemical properties of NO derivatives and on the reaction conditions alike (Srivastava et al., 2001; Baba et al., 2009). Furthermore, S-nitrosoglutathione (GSNO), the major intracellular storage and transport form of NO *in vivo*, has recently been identified as a carbonyl reductase 1 (CBR1) substrate (Bateman et al., 2008; Staab et al., 2011), whereas, at higher concentrations, GSNO inactivates human CBR1 by covalent modification of cysteine residues (Staab et al., 2011).

We have therefore studied the effect of two biologically important nitrosothiols, GSNO and SNAP, and a non-thiol-based NO donor, DEANO, on anthracycline alcohol metabolites formation.

Incubation of human heart cytosolic fractions at 37° C with different concentrations of GSNO, SNAP or DEANO led to a time- (data not shown) and dose-dependent inhibition of DOXol and DNRol formation (Fig. 7). GSNO, SNAP and DEANO, unlike ebselen and cyPGs, were more effective in inhibiting DNRol than DOXol formation (compare Fig.

7A with Fig. 7B). In fact, the inhibition of DOXol formation remains incomplete even upon increasing GSNO, SNAP or DEANO concentration and/or the incubation time, with an  $I_{\max}$  of about 76 % for GSNO and SNAP and about 65% for DEANO (Fig. 7A).

As evidenced by  $IC_{50}$  values (Fig. 7A and 7B), the inhibitory potency of GSNO and SNAP was practically similar whereas DEANO, whose action can be attributed solely to the released NO group and its subsequent chemistry (Yang et al., 2002), was considerably less effective in inhibiting anthracycline alcohol metabolites formation.

As suggested by Tao and English (Tao and English, 2004), GSNO is capable of both S-nitrosylating and S-glutathiolating reactive cysteines, and the degree of S-nitrosylation/S-glutathiolation depends upon both the protein structure and the chemistry of GSNO. Freshly prepared GSNO was more effective in S-nitrosylation of proteins through transnitrosylation reactions, whereas decomposed GSNO was more effective in S-glutathiolation of proteins (Tao and English, 2004). Therefore, we compared the effects of fresh and 72 hours-decomposed GSNO on anthracycline alcohol metabolites formation by human heart cytosol. As shown in Figure 8, decomposed GSNO was much less effective than fresh GSNO in inhibiting both DOXol and DNRol formation. Conversely, GSSG, the main GSNO dismutation product (the stoichiometry of GSSG formation by GSNO is 1:2, i.e. 1 mol of GSSG per 2 mol of GSNO), only slightly inhibited DOXol and DNRol formation save for the highest concentrations employed (see again Fig. 8) that, however, should be ruled out in our experimental conditions. It is noteworthy, indeed, that in fresh GSNO solutions, the amount of GSSG is negligible and its concentration increases minimally during the incubation period.

Also supporting the S-nitrosylation mechanism, SNAP, known to modify protein thiols exclusively by S-nitrosylation because of a S-nitroso group more sterically hindered than GSNO (Konorev et al., 2000), inhibited DOXol and DNRol formation with an efficiency

practically similar to that of GSNO (see again Fig. 7).

Very remarkably, moreover, the inhibitory effect of S-nitrosothiols on anthracycline alcohol metabolites formation was reversible. When the GSNO- or SNAP-inactivated heart cytosolic fractions were treated with DTT (10 mM) for 60 min at 37°C, most of anthracycline reductase activity was recovered ( $80 \pm 6 \%$  and  $82 \pm 5 \%$  using DOX and DNR as substrate, respectively).

**Effect of short-chain coenzyme Q analogs.** Coenzyme Q<sub>10</sub> (CoQ<sub>10</sub>) or ubiquinone is an essential component of the mitochondrial electron transport chain, playing a key role in cellular energy production (Genova and Lenaz, 2011; Orsucci et al., 2011). In its reduced hydroquinone form, coenzyme Q<sub>10</sub> is a powerful antioxidant protecting cells both directly, by preventing membrane lipid peroxidation, and/or indirectly by regenerating other antioxidants such as ascorbate and  $\alpha$ -tocopherol (Genova and Lenaz, 2011; Orsucci et al., 2011).

Preclinical and clinical studies (Conklin, 2005; van Dalen et al., 2011; Cardinale et al., 2013), albeit controversial (Greenlee et al., 2012), suggested that CoQ<sub>10</sub> might be useful in preventing or mitigating anthracycline-induced cardiotoxicity without interfering with anthracycline anti-cancer activity. Many mechanisms can be evoked for the cardioprotective action of CoQ<sub>10</sub>, but the current hypothesis suggests that CoQ<sub>10</sub> may limit anthracycline semiquinone formation and then ROS overproduction by competing with anthracyclines for the active site of mitochondrial NADH:coenzyme Q oxidoreductase (Complex I) (Conklin, 2005). Interestingly, one of the subunits of mitochondrial NADH:coenzyme Q oxidoreductase displays a strong homology with several members of short-chain dehydrogenase/reductase (SDR), a cytosolic reductase superfamily involved in anthracycline metabolism (Baker et al., 1999).

The extreme hydrophobicity of CoQ<sub>10</sub>, that precludes its use in our experimental

conditions, and the potentiality of short-chain CoQ<sub>10</sub> analogs to act as substrates and/or inhibitors of mitochondrial NADH:coenzyme Q oxidoreductase (King et al., 2009) and as substrates for several different cytosolic NADPH oxidoreductases (Jin and Penning, 2007; Malatkova et al., 2010) induced us to investigate about the eventual effect of several water soluble CoQ<sub>10</sub> analogs on anthracycline alcohol metabolites formation.

As shown in Figure 9, CoQ<sub>0</sub>, CoQ<sub>1</sub>, CoQ<sub>2</sub>, DB and IDB inhibited significantly DOXol and even more DNRol formation, with CoQ<sub>0</sub> displaying the highest efficiency, whereas CoQ<sub>4</sub>, and CoQ<sub>6</sub> were almost totally ineffective. The IC<sub>50</sub> values for short-chain CoQ<sub>10</sub> analogs are reported in Table 2.

Unlike the quinone form, the hydroquinone form of any short-chain CoQ<sub>10</sub> analog was almost totally ineffective in inhibiting (less than 5%) either DOXol or DNRol formation.

Moreover, the addition of 20 μM dicumarol into the reaction mixture together with IDB significantly enhanced quinone-dependent inhibition of both DOXol and DNRol formation (Fig. 10A, Fig. 10B and Table 2). Dicumarol, indeed, is the most potent inhibitor of NADPH-quinone oxidoreductase 1, a cytosolic flavoenzyme that catalyzes the obligatory two-electron reduction of various quinones to their hydroquinone forms (Haefeli et al., 2011; Erb et al., 2012). Dicumarol alone, instead, very slightly affected anthracycline alcohol metabolites formation (less than 5% of inhibition).

## Discussion

A pharmacological strategy aimed at inhibiting the conversion of anthracyclines into their cardiotoxic metabolites could provide a twofold advantage thwarting anthracycline-induced cardiomyopathy as well as overcoming tumor resistance towards these anticancer drugs. Since the evidence at this regard is still scarce and unsettled (Tanaka et al., 2005; Hintzpeter et al., 2015), we have initially evaluated the effects on anthracycline reductive metabolism of a variety of compounds (metal chelators, radical scavengers, antioxidants,  $\beta$ -blockers, nitron spin traps and lipid-lowering drugs) employed as protective agents against anthracycline-induced cardiotoxicity. Among the compounds here examined many have failed to significantly inhibit anthracycline alcohol metabolites formation (see Table 1), thus confirming that their cardioprotective effects against anthracycline-induced cardiotoxicity should be ascribed to their antioxidant and/or antiapoptotic properties (Gianni et al., 2008; van Dalen et al., 2011; Octavia et al., 2012; Cardinale et al., 2013). Other drugs (i.e. ebselen, cyPGs, NO donors and short-chain CoQ<sub>10</sub> analogs) have been here characterized for the first time as effective inhibitors of the enzymatic conversion of anthracyclines into their cardiotoxic metabolites.

As can be evinced from IC<sub>50</sub> values, ebselen and its derivative ebselen diselenide are the most potent inhibitors of both DOXol and DNRol formation.

Interestingly, the inhibitory potency of ebselen and, even better, ebselen diselenide is comparable to that of curcumin, one of the more potent tight-binding inhibitor of human carbonyl reductase 1 (Hintzpeter et al., 2015).

The inhibition pattern of ebselen as well as of ebselen diselenide is noncompetitive ( $K_i$  values of  $5.586 \pm 0.254$  and  $3.782 \pm 0.189$   $\mu$ M, respectively), suggesting that the two compounds are capable of inhibiting NADPH-dependent reductases by binding equally well to the free enzyme or to the enzyme-substrate complex.

Ebselen exhibits a strong electrophilic activity and is therefore capable of forming selenyl-sulfide bonds with cysteines of a variety of proteins (Zembowicz et al., 1993; Terentis et al., 2010).

In human myocardium, two different cytosolic NADPH-dependent oxidoreductases, namely carbonyl reductase 1 (CBR1, belonging to the SDR superfamily) and aldehyde reductase (AKR1A1, belonging to the AKR superfamily) are by far the most potent carbonyl reducing enzymes involved in anthracycline metabolism (Mordente et al., 2003; Salvatorelli et al., 2007; Barski et al., 2008; Bateman et al., 2008; Kassner et al., 2008). CBR1 primarily reduces DNR to DNRol whereas AKR1A1 prevalently converts DOX into DOXol (Mordente et al., 2003; Salvatorelli et al., 2007; Kassner et al., 2008).

Human CBR1 contains five cysteines located in, or close to, the active site and among them Cys227 has been identified as the residue involved in the binding of both substrate and GSH (Tinguely and Wermuth, 1999; Hartmanova et al., 2013). AKR1A1 contains six cysteines, none of which appears to be implicated in the catalytic mechanism of the enzyme (Barski et al., 2008).

It can be then inferred that ebselen is capable of inhibiting human heart anthracycline reductases by forming covalent adducts with catalytically essential (in CBR1) or non-essential cysteine residues (in AKR1A1, i.e. Cys4 and Cys259), either by increasing local hydrophobicity and/or steric hindrance with its bulky, hydrophobic aromatic groups, thereby leading to dose-dependent alterations in the protein native structure with perturbation of anthracycline binding site and inhibition of enzyme activity.

Moreover, the ebselen-protein adduct looks stable, well sheltered at or near the enzyme active site so that DTT or GSH result practically unable to rescue the native anthracycline reductase activity.

The high efficiency of ebselen (and of its intracellular storage form ebselen diselenide)

in decreasing toxic anthracycline reductive metabolism, together with unique biochemical properties and favorable pharmacological profile (low toxicity, lack of adverse effects, metabolic stability), makes ebselen a most promising cardioprotective agent against anthracycline-induced cardiotoxicity (see Figure 1).

At pharmacological concentrations (Straus and Glass, 2001), also cyPGs have been found to be potent inhibitors of anthracycline alcohol metabolites formation in isolated human heart cytosol. Structure-activity studies evidenced that the eicosanoid structure is not a prerequisite for cyPGs-induced inhibition of anthracycline alcohol metabolites formation. Conversely, the presence of a reactive  $\alpha, \beta$ -unsaturated carbonyl group in the cyclopentenone ring moiety (endocyclic  $\alpha, \beta$ -unsaturated ketone) is an absolute requirement for the PGs inhibitory activity. Indeed, PGs containing an endocyclic  $\alpha, \beta$ -unsaturated ketone (i.e.  $\text{PGA}_1$ ,  $\text{PGA}_2$ ,  $\text{PGJ}_2$ ,  $15\text{d-PGJ}_2$  and  $\Delta^{12}\text{-PGJ}_2$ ) were effective inhibitors of anthracycline alcohol metabolites formation, whereas PGs, either lacking (i.e.  $\text{PGD}_1$ ,  $\text{PGD}_2$ ,  $\text{PGE}_1$  and  $\text{PGE}_2$  as well as  $9,10\text{-dihydro-}15\text{d-PGJ}_2$ ) or containing a sterically hindered  $\alpha, \beta$ -unsaturated carbonyl group (i.e.  $\text{PGB}_1$  and  $\text{PGB}_2$ ), were ineffective. Moreover, the presence of a second, potentially reactive,  $\beta$ -carbon located on one of the two aliphatic side chains (exocyclic  $\alpha, \beta$ -unsaturated ketone) does not actually increase but instead diminishes cyPGs-mediated inhibition of DOXol formation. In fact, dienone cyPGs like  $15\text{d-PGJ}_2$  and  $\Delta^{12}\text{-PGJ}_2$  (with an endocyclic  $\beta$ -carbon at C9 and an exocyclic one at C13 position) were much less effective than single enone structure cyPGs (like  $\text{PGA}_1$  and  $\text{PGA}_2$  with an endocyclic  $\beta$ -carbon at C11 or  $\text{PGJ}_2$  with an endocyclic  $\beta$ -carbon at C9) in inhibiting DOXol formation (Fig. 6). Interestingly, the finding that cyPGs (mainly  $\text{PGA}_1$  and  $\text{PGA}_2$ ) were much more potent inhibitors of DOXol and DNRol formation than 2-cyclopenten-1-one highlights the importance for cyPGs inhibitory activity of the aliphatic side chains (cyPGs differs from 2-cyclopenten-1-one

only for the presence of the aliphatic side chains). Furthermore, the comparison of  $IC_{50}$  values of cyPGs of the A series with those of the J series evidences that the position of the ring structure in relation to the side chain configuration is fundamental in modulating the inhibitory potency of this class of eicosanoids. The highest inhibitory efficiency is indeed achieved when the carbonyl group and the  $\alpha$ -side chain (containing a carboxyl group) are on the same side of the molecule. Although the molecular mechanisms underlying the cyPGs inhibitory activity remain to be verified, it is nevertheless reasonable to postulate that cyPGs, due to their high reactivity towards protein nucleophilic residues (Michael addition) like cysteine (Renedo et al., 2007; Garzon et al., 2011) or histidine (Yamaguchi et al., 2010), may decrease the conversion of anthracyclines into their respective alcohol metabolites by covalently binding to, and irreversibly inhibiting, cytosolic reductases (e.g. AKR1A1 and/or CBR1) involved in anthracycline metabolism. At this regard, our data are in agreement with already reported findings (Diez-Dacal et al., 2011) which have identified AKR1B10, a member of the AKR superfamily involved in tumor development and cancer chemoresistance, as a selective target for  $PGA_1$  modification.  $PGA_1$  inhibited AKR1B10 and increased the accumulation of DOX in lung cancer cells, thus potentiating anthracycline anticancer effects and helping in counteracting multidrug chemoresistance.

Also NO donors are capable of regulating myocardial reductive metabolism of anthracyclines. GSNO, SNAP and, albeit less efficiently, DEANO inhibited significantly both DOXol and DNRol formation. Experiments with DTT, fresh or decomposed GSNO, and GSSG indicate that S-nitrosylation of functionally important cysteine residues of cytosolic reductases might be the prevalent mechanism accounting for nitrosothiol-dependent inhibition of cytosolic reductases.

A recent study, moreover, shows that GSNO-dependent S-glutathiolation of cysteines of



CBR1, along with the formation of a disulfide bridge between Cys226 and Cys227 (Hartmanova et al., 2013) may be also an important mechanism of enzyme regulation.

Apart from the precise molecular mechanism (S-nitrosylation and/or S-glutathiolation) underlying their inhibitory effects on human heart cytosolic reductases, NO donors prevent the development of the hypoxia-induced drug resistance (Matthews et al., 2001; Frederiksen et al., 2003).

Finally, the present study shows, for the first time, that the quinone form of short-chain CoQ<sub>10</sub> analogs is an effective inhibitor of anthracycline alcohol metabolite formation, whereas the respective hydroquinone form is completely ineffective. CoQ<sub>0</sub>, IDB and CoQ<sub>1</sub> are the most potent inhibitors of both DOXol and DNRol formation whereas quinones with a slightly longer isoprenoid side chain were much less effective (see CoQ<sub>2</sub>) or almost completely ineffective (see CoQ<sub>4</sub> and CoQ<sub>6</sub>). It is noteworthy that all the short-chain CoQ<sub>10</sub> analogs are more powerful in inhibiting DRNol than DOXol formation, probably reflecting quinones greater affinity for CBR1 than for AKR1A1.

The experiments with dicumarol confirm that: a) the quinone form of the short-chain CoQ<sub>10</sub> analogs is the functionally active form; b) IDB is a good substrate for NADPH-quinone oxidoreductase 1; c) NADPH-quinone oxidoreductase 1 is not involved in anthracycline reductive metabolism in human heart cytosol.

Mechanistically, as already suggested for mitochondrial NADH:coenzyme Q oxidoreductase, short-chain quinones might decrease anthracycline alcohol metabolite formation by competing with the anticancer drug for the active site of NADPH-dependent cytosolic reductases.

Some short-chain quinones were investigated as potential therapeutic molecules in many mitochondrial diseases (Becker et al., 2010; Erb et al., 2012; Koopman et al., 2012) but, because of their severe cytotoxic effects, extreme caution must be warranted in

therapeutic applications of these quinones (Haefeli et al., 2011).

Clinical trials have, instead, evidenced that IDB is safe (only mild adverse effects were observed) and well tolerated in single oral dose and in repeated daily doses (Kutz et al., 2009; Becker et al., 2010). IDB supplementation consistently improved cardiomyopathy commonly associated with Friedreich ataxia (Kearney et al., 2012) and, although a positive phase III study is still lacking, IDB therapy is nonetheless temporarily authorized for treating cardiomyopathy in these patients (Becker et al., 2010). Therefore, like ebselen, IDB also might be considered putatively beneficial for the treatment of anthracycline-induced cardiotoxicity.

In conclusion, this study identifies novel compounds able to significantly inhibit reductive anthracycline metabolism in reconstituted human heart cytosolic fractions as potential candidates in association therapy for the prevention or attenuation of anthracycline-induced cardiomyopathy and we hope that the results reported herein open the way, with due careful attention, to their clinical testing.

### **Authorship Contributions**

*Participated in research design:* Mordente, Silvestrini, and Meucci.

*Conducted experiments:* Mordente, Silvestrini, and Meucci.

*Contributed new reagents or analytic tools:* Mordente, Tavian, Martorana and Meucci.

*Performed data analysis:* Mordente, Tavian.

*Wrote or contributed to the writing of the manuscript:* Mordente, Silvestrini, Martorana and Meucci.

## References

- Baba SP, Wetzelberger K, Hoetker JD, and Bhatnagar A (2009) Posttranslational glutathiolation of aldose reductase (AKR1B1): a possible mechanism of protein recovery from S-nitrosylation. *Chemico-biological interactions* **178**:250-258.
- Bains OS, Grigliatti TA, Reid RE, and Riggs KW (2010) Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin. *J Pharmacol Exp Ther* **335**:533-545.
- Baker ME, Grundy WN, and Elkan CP (1999) A common ancestor for a subunit in the mitochondrial proton-translocating NADH:ubiquinone oxidoreductase (complex I) and short-chain dehydrogenases/reductases. *Cell Mol Life Sci* **55**:450-455.
- Barski OA, Tipparaju SM, and Bhatnagar A (2008) The aldo-keto reductase superfamily and its role in drug metabolism and detoxification. *Drug Metab Rev* **40**:553-624.
- Bateman RL, Rauh D, Tavshanjian B, and Shokat KM (2008) Human carbonyl reductase 1 is an S-nitrosoglutathione reductase. *J Biol Chem* **283**:35756-35762.
- Becker C, Bray-French K, and Drewe J (2010) Pharmacokinetic evaluation of idebenone. *Expert Opin Drug Metab Toxicol* **6**:1437-1444.
- Blanco JG, Sun CL, Landier W, Chen L, Esparza-Duran D, Leisenring W, Mays A, Friedman DL, Ginsberg JP, Hudson MM, Neglia JP, Oeffinger KC, Ritchey AK, Villaluna D, Relling MV, and Bhatia S (2012) Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group. *J Clin Oncol* **30**:1415-1421.
- Cardinale D, Bacchiani G, Beggiato M, Colombo A, and Cipolla CM (2013) Strategies to prevent and treat cardiovascular risk in cancer patients. *Semin Oncol* **40**:186-198.
- Conklin KA (2005) Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity. *Integr Cancer Ther* **4**:110-130.
- de Luca A, Moroni N, Serafino A, Primavera A, Pastore A, Pedersen JZ, Petruzzelli R, Farrace MG, Pierimarchi P, Moroni G, Federici G, Sinibaldi Vallebona P, and Lo Bello M (2011) Treatment of doxorubicin-resistant MCF7/Dx cells with nitric oxide causes histone glutathionylation and reversal of drug resistance. *The Biochemical journal* **440**:175-183.
- Diez-Dacal B, Gayarre J, Gharbi S, Timms JF, Coderch C, Gago F, and Perez-Sala D (2011) Identification of aldo-keto reductase AKR1B10 as a selective target for modification and inhibition by prostaglandin A(1): implications for antitumoral activity. *Cancer Res* **71**:4161-4171.
- Diez-Dacal B and Perez-Sala D (2012) A-class prostaglandins: early findings and new perspectives for overcoming tumor chemoresistance. *Cancer Lett* **320**:150-157.
- Dowd NP, Scully M, Adderley SR, Cunningham AJ, and Fitzgerald DJ (2001) Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. *J Clin Invest* **108**:585-590.

Erb M, Hoffmann-Enger B, Deppe H, Soeberdt M, Haefeli RH, Rummey C, Feurer A, and Gueven N (2012) Features of idebenone and related short-chain quinones that rescue ATP levels under conditions of impaired mitochondrial complex I. *PLoS One* **7**:e36153.

Ferguson DC, Cheng Q, and Blanco JG (2015) Characterization of the Canine Anthracycline Metabolizing Enzyme Carbonyl Reductase 1 (cbr1) and the Functional Isoform cbr1 V218. *Drug Metab Dispos*.

Frederiksen LJ, Siemens DR, Heaton JP, Maxwell LR, Adams MA, and Graham CH (2003) Hypoxia induced resistance to doxorubicin in prostate cancer cells is inhibited by low concentrations of glyceryl trinitrate. *J Urol* **170**:1003-1007.

Garzon B, Oeste CL, Diez-Dacal B, and Perez-Sala D (2011) Proteomic studies on protein modification by cyclopentenone prostaglandins: expanding our view on electrophile actions. *J Proteomics* **74**:2243-2263.

Genova ML and Lenaz G (2011) New developments on the functions of coenzyme Q in mitochondria. *Biofactors* **37**:330-354.

Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, and Sawyer DB (2008) Anthracycline cardiotoxicity: from bench to bedside. *J Clin Oncol* **26**:3777-3784.

Greenlee H, Shaw J, Lau YK, Naini A, and Maurer M (2012) Lack of effect of coenzyme q10 on Doxorubicin cytotoxicity in breast cancer cell cultures. *Integr Cancer Ther* **11**:243-250.

Haefeli RH, Erb M, Gemperli AC, Robay D, Courdier Fruh I, Anklin C, Dallmann R, and Gueven N (2011) NQO1-dependent redox cycling of idebenone: effects on cellular redox potential and energy levels. *PLoS One* **6**:e17963.

Hartmanova T, Tambor V, Lenco J, Staab-Weijnitz CA, Maser E, and Wsol V (2013) S-nitrosoglutathione covalently modifies cysteine residues of human carbonyl reductase 1 and affects its activity. *Chemico-biological interactions* **202**:136-145.

Heibein AD, Guo B, Sprowl JA, Maclean DA, and Parissenti AM (2012) Role of aldo-keto reductases and other doxorubicin pharmacokinetic genes in doxorubicin resistance, DNA binding, and subcellular localization. *BMC Cancer* **12**:381.

Hintzpeter J, Hornung J, Ebert B, Martin HJ, and Maser E (2015) Curcumin is a tight-binding inhibitor of the most efficient human daunorubicin reductase - Carbonyl reductase 1. *Chemico-biological interactions* **234**:162-168.

Jin Y and Penning TM (2007) Aldo-keto reductases and bioactivation/detoxication. *Annu Rev Pharmacol Toxicol* **47**:263-292.

Kassner N, Huse K, Martin HJ, Godtel-Armbrust U, Metzger A, Meineke I, Brockmoller J, Klein K, Zanger UM, Maser E, and Wojnowski L (2008) Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver. *Drug Metab Dispos* **36**:2113-2120.

Kearney M, Orrell RW, Fahey M, and Pandolfo M (2012) Antioxidants and other pharmacological treatments for Friedreich ataxia. *Cochrane Database Syst Rev* **4**:CD007791.

King MS, Sharpley MS, and Hirst J (2009) Reduction of hydrophilic ubiquinones by the flavin in mitochondrial NADH:ubiquinone oxidoreductase (Complex I) and production of reactive oxygen species. *Biochemistry* **48**:2053-2062.

Konorev EA, Kalyanaraman B, and Hogg N (2000) Modification of creatine kinase by S-nitrosothiols: S-nitrosation vs. S-thiolation. *Free Radic Biol Med* **28**:1671-1678.

Koopman WJ, Willems PH, and Smeitink JA (2012) Monogenic mitochondrial disorders. *N Engl J Med* **366**:1132-1141.

Kutz K, Drewe J, and Vankan P (2009) Pharmacokinetic properties and metabolism of idebenone. *J Neurol* **256 Suppl 1**:31-35.

Malatkova P, Maser E, and Wsol V (2010) Human carbonyl reductases. *Curr Drug Metab* **11**:639-658.

Matthews NE, Adams MA, Maxwell LR, Gofton TE, and Graham CH (2001) Nitric oxide-mediated regulation of chemosensitivity in cancer cells. *J Natl Cancer Inst* **93**:1879-1885.

Menna P, Gonzalez Paz O, Chello M, Covino E, Salvatorelli E, and Minotti G (2011) Anthracycline cardiotoxicity. *Expert Opin Drug Saf*.

Menna P, Salvatorelli E, and Minotti G (2008) Cardiotoxicity of antitumor drugs. *Chem Res Toxicol* **21**:978-989.

Minotti G, Menna P, Salvatorelli E, Cairo G, and Gianni L (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. *Pharmacol Rev* **56**:185-229.

Minotti G, Recalcatti S, Mordente A, Liberi G, Calafiore AM, Mancuso C, Preziosi P, and Cairo G (1998) The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase/iron regulatory protein-1 in cytosolic fractions from human myocardium. *FASEB J* **12**:541-552.

Mordente A, Meucci E, Silvestrini A, Martorana GE, and Giardina B (2009) New developments in anthracycline-induced cardiotoxicity. *Curr Med Chem* **16**:1656-1672.

Mordente A, Meucci E, Silvestrini A, Martorana GE, and Giardina B (2012) Anthracyclines and mitochondria. *Adv Exp Med Biol* **942**:385-419.

Mordente A, Minotti G, Martorana GE, Silvestrini A, Giardina B, and Meucci E (2003) Anthracycline secondary alcohol metabolite formation in human or rabbit heart: biochemical aspects and pharmacologic implications. *Biochem Pharmacol* **66**:989-998.

Mordente A, Santini SA, Miggiano AG, Martorana GE, Petiti T, Minotti G, and Giardina B (1994) The interaction of short chain coenzyme Q analogs with different redox states of myoglobin. *J Biol Chem* **269**:27394-27400.

Neilan TG, Jassal DS, Scully MF, Chen G, Deflandre C, McAllister H, Kay E, Austin SC, Halpern EF, Harmey JH, and Fitzgerald DJ (2006) Iloprost attenuates doxorubicin-induced cardiac injury in a murine model without compromising tumour suppression. *Eur Heart J* **27**:1251-1256.

Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, and Moens AL (2012) Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. *J Mol Cell Cardiol* **52**:1213-1225.

Oppermann U (2007) Carbonyl reductases: the complex relationships of mammalian carbonyl- and quinone-reducing enzymes and their role in physiology. *Annu Rev Pharmacol Toxicol* **47**:293-322.

Orsucci D, Mancuso M, Ienco EC, LoGerfo A, and Siciliano G (2011) Targeting mitochondrial dysfunction and neurodegeneration by means of coenzyme Q10 and its analogues. *Curr Med Chem* **18**:4053-4064.

Pritsos CA, Sokoloff M, and Gustafson DL (1992) PZ-51 (Ebselen) in vivo protection against adriamycin-induced mouse cardiac and hepatic lipid peroxidation and toxicity. *Biochem Pharmacol* **44**:839-841.

Renedo M, Gayarre J, Garcia-Dominguez CA, Perez-Rodriguez A, Prieto A, Canada FJ, Rojas JM, and Perez-Sala D (2007) Modification and activation of Ras proteins by electrophilic prostanoids with different structure are site-selective. *Biochemistry* **46**:6607-6616.

Saad SY, Najjar TA, and Arafah MM (2006) Cardioprotective effects of subcutaneous ebselen against daunorubicin-induced cardiomyopathy in rats. *Basic Clin Pharmacol Toxicol* **99**:412-417.

Saito I, Asano T, Sano K, Takakura K, Abe H, Yoshimoto T, Kikuchi H, Ohta T, and Ishibashi S (1998) Neuroprotective effect of an antioxidant, ebselen, in patients with delayed neurological deficits after aneurysmal subarachnoid hemorrhage. *Neurosurgery* **42**:269-277; discussion 277-268.

Sakurai T, Kanayama M, Shibata T, Itoh K, Kobayashi A, Yamamoto M, and Uchida K (2006) Ebselen, a seleno-organic antioxidant, as an electrophile. *Chem Res Toxicol* **19**:1196-1204.

Salvatorelli E, Guarnieri S, Menna P, Liberi G, Calafiore AM, Mariggio MA, Mordente A, Gianni L, and Minotti G (2006) Defective one- or two-electron reduction of the anticancer anthracycline epirubicin in human heart. Relative importance of vesicular sequestration and impaired efficiency of electron addition. *J Biol Chem* **281**:10990-11001.

Salvatorelli E, Menna P, Gianni L, and Minotti G (2007) Defective taxane stimulation of epirubicinol formation in the human heart: insight into the cardiac tolerability of epirubicin-taxane chemotherapies. *J Pharmacol Exp Ther* **320**:790-800.

Sanchez-Gomez FJ, Diez-Dacal B, Pajares MA, Llorca O, and Perez-Sala D (2010) Cyclopentenone prostaglandins with dienone structure promote cross-linking of the

chemoresistance-inducing enzyme glutathione transferase P1-1. *Molecular pharmacology* **78**:723-733.

Sarma BK and Mugesh G (2008) Antioxidant activity of the anti-inflammatory compound ebselen: a reversible cyclization pathway via selenenic and seleninic acid intermediates. *Chemistry* **14**:10603-10614.

Schewe C, Schewe T, and Wendel A (1994) Strong inhibition of mammalian lipoxygenases by the antiinflammatory seleno-organic compound ebselen in the absence of glutathione. *Biochem Pharmacol* **48**:65-74.

Semianrio-Vidal L, van Hesuden C, Mugesh G, and Lazarowski ER (2010) Ebselen is a potent non-competitive inhibitor of extracellular nucleoside diphosphokinase. *Purinergic Signal* **6**:383-391.

Sies H and Masumoto H (1997) Ebselen as a glutathione peroxidase mimic and as a scavenger of peroxynitrite. *Adv Pharmacol* **38**:229-246.

Silvestrini A, Meucci E, Vitali A, Giardina B, and Mordente A (2006) Chalcone inhibition of anthracycline secondary alcohol metabolite formation in rabbit and human heart cytosol. *Chem Res Toxicol* **19**:1518-1524.

Srivastava S, Dixit BL, Ramana KV, Chandra A, Chandra D, Zacarias A, Petrash JM, Bhatnagar A, and Srivastava SK (2001) Structural and kinetic modifications of aldose reductase by S-nitrosothiols. *The Biochemical journal* **358**:111-118.

Staab CA, Hartmanova T, El-Hawari Y, Ebert B, Kisiela M, Wsol V, Martin HJ, and Maser E (2011) Studies on reduction of S-nitrosoglutathione by human carbonyl reductases 1 and 3. *Chemico-biological interactions* **191**:95-103.

Straus DS and Glass CK (2001) Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. *Medicinal research reviews* **21**:185-210.

Straus DS, Pascual G, Li M, Welch JS, Ricote M, Hsiang CH, Sengchanthalangsy LL, Ghosh G, and Glass CK (2000) 15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. *Proc Natl Acad Sci U S A* **97**:4844-4849.

Tanaka M, Bateman R, Rauh D, Vaisberg E, Ramachandani S, Zhang C, Hansen KC, Burlingame AL, Trautman JK, Shokat KM, and Adams CL (2005) An unbiased cell morphology-based screen for new, biologically active small molecules. *PLoS Biol* **3**:e128.

Tao L and English AM (2004) Protein S-glutathiolation triggered by decomposed S-nitrosoglutathione. *Biochemistry* **43**:4028-4038.

Terentis AC, Freewan M, Sempertegui Plaza TS, Raftery MJ, Stocker R, and Thomas SR (2010) The selenazal drug ebselen potently inhibits indoleamine 2,3-dioxygenase by targeting enzyme cysteine residues. *Biochemistry* **49**:591-600.

Tinguely JN and Wermuth B (1999) Identification of the reactive cysteine residue (Cys227) in human carbonyl reductase. *Eur J Biochem* **260**:9-14.



Tokarska-Schlattner M, Zaugg M, Zuppinger C, Wallimann T, and Schlattner U (2006) New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics. *J Mol Cell Cardiol* **41**:389-405.

van Dalen EC, Caron HN, Dickinson HO, and Kremer LC (2011) Cardioprotective interventions for cancer patients receiving anthracyclines. *Cochrane Database Syst Rev*:CD003917.

Yamaguchi S, Aldini G, Ito S, Morishita N, Shibata T, Vistoli G, Carini M, and Uchida K (2010) Delta12-prostaglandin J2 as a product and ligand of human serum albumin: formation of an unusual covalent adduct at His146. *J Am Chem Soc* **132**:824-832.

Yamaguchi T, Sano K, Takakura K, Saito I, Shinohara Y, Asano T, and Yasuhara H (1998) Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial. Ebselen Study Group. *Stroke* **29**:12-17.

Yang ES, Richter C, Chun JS, Huh TL, Kang SS, and Park JW (2002) Inactivation of NADP(+)-dependent isocitrate dehydrogenase by nitric oxide. *Free Radic Biol Med* **33**:927-937.

Zembowicz A, Hatchett RJ, Radziszewski W, and Gryglewski RJ (1993) Inhibition of endothelial nitric oxide synthase by ebselen. Prevention by thiols suggests the inactivation by ebselen of a critical thiol essential for the catalytic activity of nitric oxide synthase. *J Pharmacol Exp Ther* **267**:1112-1118.

Zhao R and Holmgren A (2002) A novel antioxidant mechanism of ebselen involving ebselen diselenide, a substrate of mammalian thioredoxin and thioredoxin reductase. *J Biol Chem* **277**:39456-39462.

Zhu SG, Kukreja RC, Das A, Chen Q, Lesnefsky EJ, and Xi L (2011) Dietary nitrate supplementation protects against Doxorubicin-induced cardiomyopathy by improving mitochondrial function. *J Am Coll Cardiol* **57**:2181-2189.

## **Funding**

This work was partially supported by Grants from Catholic University, Linea D1 Roma

[Grant: 70200375]

## Figure Legends

**Fig. 1.** Scheme of ebselen inhibition of myocardial cytosolic reductases responsible for the formation of anthracycline cardiotoxic metabolites.

**Fig. 2.** Effect of ebselen and ebselen diselenide on anthracycline secondary alcohol metabolites formation. Experiments were performed by incubating human heart cytosolic fractions (1 mg protein/ml) in standard buffer, at 37 °C with or without (vehicle) different concentrations of ebselen (**A**) or ebselen diselenide (**B**) added 5 min before 50 μM DOX or DNR. Reactions were started by adding 250 μM NADPH. DOXol (■) or DNRol (●) were assayed after 240 min at 37 °C as described in the Materials and Methods section. Values are the means ± S.E. of three separate experiments performed in triplicate. The IC<sub>50</sub> values are determined as described in the Materials and Methods section.

**Fig. 3.** Lineweaver-Burk plots for the inhibition of DOXol formation by ebselen (**A**) or ebselen diselenide (**B**). Experiments were performed by incubating human heart cytosolic fractions (1 mg protein/ml) in standard buffer, at 37 °C with 0 μM (◆), 10 μM (●), 17 μM (▲), and 25 μM (■) of ebselen (panel **A**) or with 0 μM (◆), 2.5 μM (●), 5 μM (▲), and 10 μM (■) of ebselen diselenide (panel **B**) in presence of increasing concentrations of DOX (25-500 μM). Reactions were started by adding 250 μM NADPH. Alcohol metabolites were assayed after 240 min at 37 °C as described in the Materials and Methods section. Values are the means ± S.E. of three separate experiments performed in triplicate.

**Fig. 4.** Effect of different classes of prostaglandins on anthracycline secondary alcohol metabolites formation. Experiments were performed by incubating human heart cytosolic fractions (1 mg protein/ml) in standard buffer, at 37 °C with or without (vehicle) of 100 μM of each prostaglandin added 5 min before 50 μM DOX (**A**) or DNR (**B**). Reactions were started by adding 250 μM NADPH. Alcohol metabolites were assayed after 240 min at 37 °C as described in the Materials and Methods section. Values are the means ± S.E. of at least three separate experiments performed in triplicate. Statistical probability (*P*) is expressed as follows: \* *P* < 0.05, \*\* *P* < 0.01, and \*\*\**P* < 0.001.

**Fig. 5.** Effect of cyclopentenone prostaglandins on anthracycline secondary alcohol metabolites formation. Experiments were performed by incubating human heart cytosolic fractions (1 mg protein/ml) in standard buffer, at 37 °C with or without (vehicle) different concentrations of PGA<sub>1</sub> (■), PGA<sub>2</sub> (●), PGJ<sub>2</sub> (□), 15d-PGJ<sub>2</sub> (○), and Δ<sup>12</sup>-PGJ<sub>2</sub> (◇) added 5 min before 50 μM DOX (**A**) or DNR (**B**). Reactions were started by adding 250 μM NADPH. Alcohol metabolites were assayed after 240 min at 37 °C as described in the Materials and Methods section. Values are the means ± S.E. of at least three separate experiments performed in triplicate.

**Fig. 6.** Structures and IC<sub>50</sub> values of the most active cyPGs employed in the study. Experimental details are described in Fig. 5. The IC<sub>50</sub> values are determined as described in the Materials and Methods section.

**Fig. 7.** Effect of nitric oxide donors on anthracycline secondary alcohol metabolites formation. Experiments were performed by incubating human heart cytosolic fractions (1 mg protein/ml) in standard buffer, for 120 min at 37 °C with or without (vehicle)

different concentrations of GSNO (●), SNAP (■) and DEANO (▲). After removal of tested compound (see Materials and Methods), 50 μM DOX (A) or DNR (B) was added into the mixture and the reaction was started by adding 250 μM NADPH. Alcohol metabolites were assayed after 240 min at 37 °C as described in the Materials and Methods section. Values are the means ± S.E. of at least three separate experiments performed in triplicate. The IC<sub>50</sub> values are determined as described in the Materials and Methods section.

**Fig. 8.** Effect of fresh or 72h-decomposed GSNO and GSSG on anthracycline secondary alcohol metabolites formation. Experiments were performed by incubating human heart cytosolic fractions (1 mg protein/ml) in standard buffer for 60 min at 37 °C with or without (vehicle) different concentrations of fresh or 72h-decomposed GSNO and GSSG. After removal of tested compound (see Materials and Methods section.), 50 μM DOX (A) or DNR (B) was added into the mixture and the reaction was started by adding 250 μM NADPH. Alcohol metabolites were assayed after 240 min at 37 °C as described in the Materials and Methods section. Values are the means ± S.E. of at least three separate experiments performed in triplicate. Statistical probability (*P*) is expressed as follows: \* *P* < 0.05, \*\* *P* < 0.01, and \*\*\**P* < 0.001.

**Fig. 9.** Effect of short-chain CoQ analogs on anthracycline secondary alcohol metabolites formation. Experiments were performed by incubating human heart cytosolic fractions (1 mg protein/ml) in standard buffer, at 37 °C with or without (vehicle) 50 μM of each short-chain CoQ analog added 5 min before 50 μM DOX (A) or DNR (B). Reactions were started by adding 250 μM NADPH. Alcohol metabolites were assayed after 240 min at 37 °C as described in the Materials and Methods section. Values are the means ± S.E. of at least three separate experiments performed in triplicate. Statistical probability (*P*) is expressed as follows: \* *P* < 0.05, \*\* *P* < 0.01, and \*\*\**P* < 0.001.

**Fig. 10.** Effect of CoQ<sub>0</sub> and IDB on anthracycline secondary alcohol metabolites formation. Experiments were performed by incubating human heart cytosolic fractions (1 mg protein/ml) in standard buffer, at 37 °C with or without (vehicle) different concentrations of CoQ<sub>0</sub> (●), IDB (■) or IDB plus 20 μM dicumarol (□) added 5 min before 50 μM DOX (A) or DNR (B). Reactions were started by adding 250 μM NADPH. Alcohol metabolites were assayed after 240 min at 37 °C as described in the Materials and Methods section. Values are the means ± S.E. of at least three separate experiments performed in triplicate.

TABLE 1. Effect of metal chelators, radical scavengers, antioxidants,  $\beta$ -blockers, nitron spin traps and lipid-lowering drugs on the formation of anthracycline secondary alcohol metabolites by human heart cytosolic fractions<sup>a</sup>.

| Compound                   | % of inhibition |                 |
|----------------------------|-----------------|-----------------|
|                            | DOXol formation | DNRol formation |
| Dexrazoxane                | 4 $\pm$ 5       | 5 $\pm$ 5       |
| Melatonin                  | 3 $\pm$ 4       | 8 $\pm$ 5       |
| $\alpha$ -tocopherol       | 5 $\pm$ 2       | 6 $\pm$ 3       |
| Trolox                     | 4 $\pm$ 2       | 8 $\pm$ 4       |
| Amifostine                 | 4 $\pm$ 2       | 7 $\pm$ 4       |
| Carvedilol                 | 8 $\pm$ 4       | 6 $\pm$ 4       |
| Adenosine                  | 3 $\pm$ 2       | 5 $\pm$ 3       |
| PBN                        | 3 $\pm$ 2       | 7 $\pm$ 4       |
| POBN                       | 4 $\pm$ 3       | 5 $\pm$ 3       |
| Lovastatin                 | 7 $\pm$ 4       | 5 $\pm$ 4       |
| Mevastatin                 | 2 $\pm$ 2       | 3 $\pm$ 2       |
| All- <i>trans</i> -retinal | 2 $\pm$ 4       | 29 $\pm$ 4      |

<sup>a</sup>Experiments were performed by incubating cytosolic fractions (1 mg protein/ml) in standard buffer, at 37 °C with or without (vehicle) 100  $\mu$ M of each compound added 5 min before DOX or DNR addition (50  $\mu$ M, final concentration). Reactions were started by adding NADPH (250  $\mu$ M, final concentration). Alcohol metabolites were assayed after 240 min at 37 °C as described in the Materials and Methods section. Xenobiotic stock solutions were prepared just before use as follows: melatonin, all-*trans*-retinal and  $\alpha$ -tocopherol, 5 mM, carvedilol, lovastatin and mevastatin, 10 mM in absolute ethanol; trolox, adenosine and amifostine, 5 mM, dexrazoxane, 12.5 mM in standard buffer; POBN and PBN, 100 mM in dimethyl sulfoxide.

Values are the means  $\pm$  S.E. of at least three separate experiments performed in triplicate.


TABLE 2. Inhibitory parameters of short-chain coenzyme Q analogs on DOXol and DNRol formation by human heart cytosolic fractions<sup>a</sup>.



| Compound                   | DOX                      |                         | DNR                      |                         |
|----------------------------|--------------------------|-------------------------|--------------------------|-------------------------|
|                            | (IC <sub>50</sub> ) (μM) | (I <sub>max</sub> ) (%) | (IC <sub>50</sub> ) (μM) | (I <sub>max</sub> ) (%) |
| CoQ <sub>0</sub>           | 11.5 ± 0.6               | 103.6 ± 1.7             | 10.1 ± 1.2               | 100.9 ± 0.6             |
| CoQ <sub>1</sub>           | 151.5 ± 9.3              | 98.7 ± 3.8              | 77.8 ± 5.1               | 102.1 ± 3.0             |
| CoQ <sub>2</sub>           | n.d. <sup>b</sup>        | n.d. <sup>b</sup>       | 93.5 ± 7.4               | 103.0 ± 4.1             |
| DB                         | 198.9 ± 8.6              | 102.3 ± 5.4             | 150.7 ± 9.0              | 101.1 ± 4.2             |
| IDB                        | 94.3 ± 6.7               | 99.4 ± 4.1              | 58.5 ± 4.4               | 98.3 ± 2.8              |
| IDB plus Dicumarol (20 μM) | 27.0 ± 1.7               | 98.7 ± 3.3              | 21.6 ± 3.2               | 101.7 ± 0.9             |

<sup>a</sup>Experiments were performed by incubating cytosolic fractions (1 mg protein/ml) in standard buffer, at 37 °C with or without (vehicle) different concentrations of each short-chain coenzyme Q analog added 5 min before DOX or DNR (50 μM, final concentration). Reactions were started by adding NADPH (250 μM, final concentration). Alcohol metabolites were assayed after 240 min at 37 °C as described in the Materials and Methods section. Values are the means ± S.E. of three separate experiments performed in triplicate. The IC<sub>50</sub> values are determined as described in the Materials and Methods section.

<sup>b</sup>Not determinable.

Figure 1



**Figure 2**











**Figure 3**


Figure 4




**Figure 5**

**Figure 6**


| Structures of cyPGs  | IC <sub>50</sub> (μM) |
|--|-----------------------|
|  <p><b>PGA<sub>1</sub></b></p>                  | <b>46.9 ± 2.4</b>     |
|  <p><b>PGA<sub>2</sub></b></p>                  | <b>69.0 ± 3.3</b>     |
|  <p><b>PGJ<sub>2</sub></b></p>                 | <b>113.1 ± 17.4</b>   |
|  <p><b>15-d-PGJ<sub>2</sub></b></p>           | <b>167.6 ± 14.7</b>   |
|  <p><b>Δ<sup>12</sup>-PGJ<sub>2</sub></b></p> | <b>339.1 ± 62.3</b>   |

**Figure 7**

**Figure 8**



**Figure 9**



**Figure 10**